Skip to main content
    P

    Praxis Precision Medicines Inc (PRAX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $310.27
    -17.86 (-5.44%)

    Market Cap: $9.17B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Praxis Precision Medicines Inc (PRAX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Praxis Precision Medicines (PRAX) to earn -$13.47 per share in the fiscal year ending Dec 31, 2026, on revenue of $869610. Of 21 analysts, 19 rate the stock Buy or Strong Buy, 1 Hold and 1 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$9.30.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 21 ratings average 1.95, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 90% of the ratings.

    RatingAnalystsShare
    Strong Buy419.0%
    Buy1571.4%
    Hold14.8%
    Sell14.8%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    21

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 39710.9%.

    Fiscal year ending Dec 31, 2026
    -$13.47
    EPS consensus, revenue $869610
    Fiscal year ending Dec 31, 2027
    -$9.30
    EPS consensus, revenue $346.20M
    Next report
    Feb 17, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$13.47-$14.10 to -$12.7413$869610N/A17
    Dec 31, 2027-$9.30-$16.18 to $5.2518$346.20M$140.23M to $674.40M19

    Quarterly Estimates

    The EPS consensus rises from -$4.00 for the quarter ending Dec 31, 2026 to -$3.75 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$4.00-$5.04 to -$1.0523$633359N/A21
    Mar 31, 2027-$3.75-$5.50 to $1.9411$31.84M$4.00M to $190.10M11

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 4 upward and 4 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202600
    Fiscal year ending Dec 31, 202712
    Quarter ending Mar 31, 202732

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$13.94.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$13.47-$14.02-$13.94-$13.94-$13.94N/A
    Fiscal year ending Dec 31, 2027-$9.30-$9.50-$9.33-$9.29-$9.41N/A
    Quarter ending Mar 31, 2027-$3.75-$3.99-$3.90-$3.89-$3.88N/A

    Frequently Asked Questions About PRAX

    What is the PRAX stock forecast?

    Consensus analyst estimates put Praxis Precision Medicines's EPS at -$13.47 for the fiscal year ending Dec 31, 2026, on revenue of $869610. The consensus rating from 21 analysts is Buy.

    How do analysts rate PRAX stock?

    Of 21 analysts covering Praxis Precision Medicines, 4 rate it Strong Buy, 15 Buy, 1 Hold, 1 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from PRAX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$13.47, with estimates from -$14.10 to -$12.74 from 13 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$9.30, with estimates from -$16.18 to $5.25 from 18 analysts.

    What revenue do analysts expect from Praxis Precision Medicines next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $869610. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $346.20M, with estimates from $140.23M to $674.40M.

    How many analysts cover PRAX?

    21 analysts rate Praxis Precision Medicines stock, and 13 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.